Valion Bio, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Valion Bio announced positive safety results from a National Institute of Allergy and Infectious Diseases (NIAID)/Radiation and Nuclear Countermeasures Program-funded study conducted by the Armed Forces Radiobiology Research Institute (AFRRI) on Entolimod, its lead biologic candidate for acute radiation syndrome. A single subcutaneous injection of Entolimod at 0.72 mg/kg in 20 male C57BL/6 mice demonstrated no treatment-related toxicity, with stable body weight, unchanged hematologic profiles, and normal organ/metabolic function across all measured parameters over a 14-day observation period. The positive safety data de-risks the program and enables advancement to a fully government-funded therapeutic efficacy study focusing on survival and gastrointestinal recovery following radiation exposure.
Why this rating
Preclinical safety validation in fully-funded government study reduces development risk for micro-cap ($4M) biotech. Positions lead asset for FDA Animal Rule pathway, critical for ARS indication where human trials infeasible. Material de-risking milestone.
Price action (we called it positive)
before filing · preread $0.68 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.